| IL-6 inhibitors in the treatment of serious COVID-19: a promising therapy? S Atal, Z Fatima Pharmaceutical medicine 34 (4), 223-231, 2020 | 165 | 2020 |
| Diabetes care during COVID-19 lockdown at a tertiary care centre in India R Joshi, S Atal, Z Fatima, S Balakrishnan, S Sharma, A Joshi diabetes research and clinical practice 166, 108316, 2020 | 36 | 2020 |
| Approval of itolizumab for COVID-19: a premature decision or need of the hour? S Atal, Z Fatima, S Balakrishnan BioDrugs 34 (6), 705-711, 2020 | 27 | 2020 |
| Remogliflozin: the new low cost SGLT-2 inhibitor for type 2 diabetes mellitus S Atal, Z Fatima, S Singh, S Balakrishnan, R Joshi Diabetology international 12 (3), 247-253, 2021 | 20 | 2021 |
| Medication adherence, recall periods and factors affecting it: a community‐based assessment on patients with chronic diseases in urban slums S Atal, A Ray, SN Ahmed, P Singh, Z Fatima, B Sadasivam, A Pakhare, ... International Journal of Clinical Practice 75 (8), e14316, 2021 | 5 | 2021 |
| Pattern of disease and therapy for diabetes along with impact of generic prescribing on cost of treatment among outpatients at a tertiary care facility. JN Atal S, Joshi R, Balakrishnan S, Singh P, Fatima Z J Pharm Bioall Sci 0;0:0, 2020 | 4* | 2020 |
| Implications and economic impact of applying international guidelines and recommendations to the management of high-risk group of type 2 diabetes mellitus patients in India Z Fatima, S Atal, R Joshi, B Sadasivam Cureus 14 (2), 2022 | 3 | 2022 |
| Comparative analysis of efficacy and adverse effects of tacrolimus vs cyclosporine in chronic dry eye disease: a tertiary care hospital based study. SSP Zeenat F, Chaurasia RC Int J Basic Clin Pharmacol, 2216-22., 2018 | 2 | 2018 |
| Metformin recalls: regulatory background, concerns and challenges B Sadasivam, Z Fatima, S Atal Wiener klinische Wochenschrift 133 (15), 851-854, 2021 | 1 | 2021 |
| Linagliptin: Cardiovascular and renal safety beyond doubt at a steep price. JR Atal S, Fatima Z, Balakrishnan S J Pharmacol Pharmacother, 35-43, 2020 | 1 | 2020 |
| CO56 Comparative Effectiveness of Teneligliptin Versus Glimepiride as Add on Medications for Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin S Atal, R Joshi, Z Fatima, S Balakrishnan, S Das, S Vaidya Value in Health 25 (12), S28, 2022 | | 2022 |
| Patterns of drug therapy, glycemic control, and predictors of escalation–non-escalation of treatment among diabetes outpatients at a tertiary care center S Atal, R Joshi, S Misra, Z Fatima, S Sharma, S Balakrishnan, P Singh Journal of Basic and Clinical Physiology and Pharmacology 33 (6), 803-814, 2022 | | 2022 |
Shubham AtalAll India Institute of Medical Sciences Bhopal在 aiimsbhopal.edu.in 的电子邮件经过验证
